DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares

Posted by Francis Steltz on Sep 17th, 2026

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Michael Brown sold 1,700 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $142,868.00. Following the transaction, the executive vice president owned 99,885 shares in the company, valued at $8,394,335.40. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

DXCM opened at $87.34 on Thursday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59. The company’s 50 day simple moving average is $83.52 and its 200 day simple moving average is $73.07. The stock has a market capitalization of $32.96 billion, a PE ratio of 34.52, a P/E/G ratio of 1.45 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 earnings per share. As a group, sell-side analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Royal Bank Of Canada upped their target price on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Finally, Benchmark boosted their price target on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

View Our Latest Research Report on DexCom

Institutional Investors Weigh In On DexCom

Institutional investors have recently made changes to their positions in the company. Plato Investment Management Ltd acquired a new stake in DexCom during the 2nd quarter worth about $782,000. Aurora Investment Counsel acquired a new position in DexCom in the 2nd quarter worth about $2,340,000. E Fund Management Co. Ltd. purchased a new stake in shares of DexCom during the 2nd quarter worth about $1,273,000. Performance Wealth Partners LLC purchased a new stake in shares of DexCom during the 2nd quarter worth about $1,740,000. Finally, Silvant Capital Management LLC acquired a new stake in shares of DexCom during the 2nd quarter valued at about $5,359,000. 97.75% of the stock is currently owned by institutional investors.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

Positive Sentiment: Expanded leadership role: CFO Jereme Sylvain will also serve as chief operating officer, potentially improving coordination between DexCom’s financial and operational functions as the company expands its continuous glucose-monitoring business. DexCom CFO Jereme Sylvain to Take Additional Role of COO
Positive Sentiment: Strong recent financial results: DexCom’s latest quarterly report exceeded expectations, with earnings per share of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, supporting the growth outlook for its G7 and other CGM products.
Positive Sentiment: Generally favorable analyst view: The stock carries a “Moderate Buy” consensus rating, with recent bullish targets including $95 from Stifel, $96 from UBS and $105 from Robert W. Baird. The average published target is $88.71, suggesting relatively limited but still positive upside based on the cited estimates.
Neutral Sentiment: Insider selling appears scheduled: EVP Michael Brown sold 1,700 shares, while Director Nicholas Augustinos sold a combined 8,089 shares. Because the transactions were conducted under pre-arranged trading plans, they may reflect routine diversification rather than a negative view of DexCom’s prospects. DexCom insider transaction filing
Negative Sentiment: Multiple insider sales could weigh on sentiment: The recent sales, including EVP Jereme Sylvain’s disposal of 3,638 shares for approximately $303,000, add a short-term cautionary signal even though the executives retained substantial holdings. DexCom insider selling report

DexCom Company Profile

(Get Free Report)

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.